Zydus Lifesciences shares rose over 6% after strong Q4FY26 earnings, reporting a 14.6% increase in net profit to ₹1,592.9 crore. Revenue grew to ₹7,587 crore, driven by the consumer wellness segment. The board approved a ₹1,100 crore share buyback and a Re 1 dividend.